Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nate N. Waldron"'
Autor:
Daniel A. Vallera, Nate N. Waldron
Publikováno v:
Antibodies, Vol 2, Iss 1, Pp 82-92 (2013)
Targeting and killing specific cells discriminately has been the goal of targeted therapy dating back to the era of Paul Ehrlich. The discovery of cancer stem cells has caused a paradigm shift within the cancer field and provided an opportunity to us
Externí odkaz:
https://doaj.org/article/9c73de551190493ca95535afbd8ab624
Autor:
Seung Uk Oh, Kristin L.M. Boylan, Amy P.N. Skubitz, Elizabeth Taras, Angela Panoskaltsis-Mortari, Nate N. Waldron, Daniel A. Vallera
Publikováno v:
Gynecologic Oncology. 130:579-587
While most women with ovarian cancer will achieve complete remission after treatment, the majority will relapse within two years, highlighting the need for novel therapies. Cancer stem cells (CSC) have been identified in ovarian cancer and most other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3601a609e4b8a3ab212de3baf1f190
https://doi.org/10.1016/j.ygyno.2013.05.027
https://doi.org/10.1016/j.ygyno.2013.05.027
Publikováno v:
Targeted Oncology. 9:239-249
The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody frag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2246abe9d8ef8a736be15f88c14a9f7f
https://doi.org/10.1007/s11523-013-0290-9
https://doi.org/10.1007/s11523-013-0290-9
Autor:
Michael R. Olin, Jayanth Panyam, Lin Niu, Steve Kalscheuer, Suresh Kumar Swaminathan, Daniel A. Vallera, David M. Zellmer, John R. Ohlfest, Nate N. Waldron
Publikováno v:
Drug Delivery and Translational Research. 3:143-151
CD133, also known as Prominin-1, is expressed on stem cells present in many tissues and tumors. In this work, we have identified and characterized a single-chain variable fragment (scFv) for the efficient and specific recognition of CD133. Phage disp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9a61914981e6f661339d80375e69ec
https://doi.org/10.1007/s13346-012-0099-6
https://doi.org/10.1007/s13346-012-0099-6
Autor:
Nate N. Waldron, Shoko Toma, David M. Zellmer, John R. Ohlfest, Seung Uk Oh, Daniel A. Vallera, Suresh Kumar Swaminathan, Jayanth Panyam
Publikováno v:
Drug Delivery and Translational Research. 3:195-204
CD133 expression enriches for tumor-initiating cells and is a negative prognostic factor in numerous cancers. We previously developed an immunotoxin against CD133 by fusing a gene fragment encoding the scFv portion of an anti-CD133 antibody to a gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c597015f81613522922e55b0cc4ae0c
https://doi.org/10.1007/s13346-012-0066-2
https://doi.org/10.1007/s13346-012-0066-2
Autor:
Daniel A. Vallera, Seung Uk Oh, John R. Ohlfest, Zintis Inde, Dan S. Kaufman, Nate N. Waldron, Melinda K. Hexum
Publikováno v:
Molecular Cancer Therapeutics. 10:1829-1838
A novel anticancer agent was constructed by fusing a gene encoding the scFV that targets both glycosylated and unglycosylated forms of CD133 to a gene fragment encoding deimmunized PE38KDEL. The resulting fusion protein, dCD133KDEL, was studied to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a84b657fb66f8d995798c55584c798
https://doi.org/10.1158/1535-7163.mct-11-0206
https://doi.org/10.1158/1535-7163.mct-11-0206
Autor:
Christopher L. Moertel, Brian M. Andersen, Rob L. Shaver, G. Elizabeth Pluhar, Nate N. Waldron, Michael R. Olin
Anti-tumor immunotherapy using tumor lysate–based vaccines has made great advances over recent decades. Cancer vaccines aim to elicit adaptive immune responses through various pathways by providing tumor and tumor-associated antigens with an immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a7ec8261ee53c731121bdcc4d8461f
https://europepmc.org/articles/PMC4485925/
https://europepmc.org/articles/PMC4485925/
Publikováno v:
Oral oncology. 48(12)
Summary Objectives To investigate the efficacy of the bispecific targeted toxin, dEGFATFKDEL, on head and neck carcinoma cell lines in vitro and in vivo. Materials and Methods A deimmunized bispecific anti-cancer agent was constructed to simultaneous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e549d1b747327d8ebc1a34d1431b0fb5
https://pubmed.ncbi.nlm.nih.gov/22818892
https://pubmed.ncbi.nlm.nih.gov/22818892
Autor:
Rebecca S. LaRue, Christopher L. Moertel, Michael R. Olin, Matthew A. Hunt, Junzhe Xia, Nate N. Waldron, Christopher A. Pennell, Robert M. Prins, Nicholas K. Foreman, Andrew M. Donson, Hideho Okada, Brian M. Andersen
Publikováno v:
Journal for Immunotherapy of Cancer
Background Immunological quiescence in the central nervous system (CNS) is a potential barrier to immune mediated anti-tumor response. One suppressive mechanism results from the interaction of parenchyma-derived CD200 and its receptor on myeloid cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48e7c34e6b196a2f380b16d1c4e0de6d
Autor:
Waldron, Nate N.1, Vallera, Daniel A.2 valle001@umn.edu
Publikováno v:
Antibodies (2073-4468). Mar2013, Vol. 2 Issue 1, p82-92. 12p.